MILTON PACKER, M. D.; WAI HUNG LEE, M.D.; NORMA MEDINA, R.N.; MADELINE YUSHAK, R.N.; PAUL D. KESSLER, M.D.
Renal function was evaluated in 104 patients with severe chronic heart failure whom we treated with Captopril or enalapril. Seventy patients showed no change or an improvement in renal function (group A)1 and 34 patients developed functional renal insufficiency (group B). Before converting-enzyme inhibition, group B patients received higher doses of furosemide (p < 0.02) and had lower central venous pressures (p < 0.05) than group A patients. After 1 to 3 months of converting-enzyme inhibition, an excessive reduction in left ventricular filling pressure (to less than 15 mm Hg) or mean arterial pressure (to less than 60 mm Hg) was noted in 28 of 34 (82%) patients in group B but in only 22 of 70 patients in group A (31%) (p < 0.001). At the end of the study, drug-induced azotemia resolved after a reduction in the dosage of diuretics, despite unaltered treatment with Captopril and enalapril. Hence, the deterioration of renal function after converting-enzyme inhibition in heart failure is not a toxic or immunologic reaction to therapy but results from specific hemodynamic events that can be ameliorated by sodium repletion.
Learn more about subscription options.
Register Now for a free account.
PACKER M, LEE WH, MEDINA N, YUSHAK M, KESSLER PD. Functional Renal Insufficiency During Long-Term Therapy with Captopril and Enalapril in Severe Chronic Heart Failure. Ann Intern Med. 1987;106:346–354. doi: 10.7326/0003-4819-106-3-346
Download citation file:
Published: Ann Intern Med. 1987;106(3):346-354.
Cardiology, Coronary Risk Factors, Heart Failure, Hypertension, Nephrology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only